Shots:

• The company has published the preclinical data from its COVID-19 vaccination program- leading to the introduction of T-VIVA-19 as novel targeted protein vaccine
• If approved- Sorrento will deploy its cGMP manufacturing facility- capable of producing bulk drug substance rS1-Fc for up to 100M doses/ month- with on-site scale-up potential to meet the required demand
• T-VIVA-19 is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (rS1-Fc). The company is planning for clinical trial clearance for the therapy while preparing for large scale manufacturing and commercial distribution in parallel

Click here to read full press release/ article | Ref: Sorrento Therapeutics  | Image: Twitter

Related News: Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates